THE ROLE OF SARCOPENIA INDEX AS A MARKER FOR MUSCULOSKELETAL HEALTH EVALUATION IN TYPE 2 DIABETES PATIENTS

Doan Truc Quynh1, Nguyen Thi Le2, Le Quoc Tuan2
1 School of Medicine, University of Medicine and Pharmacy of Ho Chi Minh City
2 Faculty of Medicine, Van Lang University

Main Article Content

Abstract

Objectives: This study aimed to investigate the association between sarcopenia index and muscle health indicators and to evaluate the incremental value of sarcopenia index in sarcopenia predictive models.


Methods: This cross-sectional study included 74 patients with type 2 diabetes mellitus aged ≥ 50 years who attended the Outpatient Department of the University Medical Center Ho Chi Minh City - Campus 2 from May to October 2025. Sarcopenia was diagnosed using the AWGS (2025) criteria (low ASM/BMI and low handgrip strength). Sarcopenia index was calculated as serum creatinine × eGFRcys, with eGFRcys estimated by the CKD-EPI 2012 cystatin C-based equation. The diagnostic performance of the conventional model (model 1) and the sarcopenia index-augmented model (model 2) was assessed using ROC curves.


Results: The prevalence of sarcopenia and severe sarcopenia was 41.9% and 12.2%, respectively. Sarcopenia index was positively correlated with ASM/BMI (r = 0.38, p < 0.001) and handgrip strength (r = 0.52, p < 0.001). Integrating sarcopenia index significantly improved diagnostic accuracy, with the AUC increasing from 0.8492 (model 1) to 0.8807 (model 2). Sarcopenia index was identified as an independent predictor (OR = 1.06; p = 0.018).


Conclusion: The sarcopenia index is a useful biochemical marker that enhances diagnostic accuracy for sarcopenia when combined with traditional methods. It holds potential as a practical, low-cost screening tool in outpatient settings.

Article Details

References

[1] Lee Y.H, Kim J.S, Jung S.W et al. Gait speed and handgrip strength as predictors of all-cause mortality and cardiovascular events in hemodialysis patients. BMC Nephrol, 2020, 21 (1): 166. doi: 10.1186/s12882-020-01831-8
[2] Zheng X, Ren X, Jiang M, Han L, Zhong C. Association of sarcopenia with rapid kidney function decline and chronic kidney disease in adults with normal kidney function. British Journal of Nutrition, 2024, 131 (5): 821-828. doi: 10.1017/S0007114523002313
[3] Yim J, Son N.H, Kim K.M et al. Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation. Front Med (Lausanne), 2022, 9: 1021936. doi: 10.3389/fmed.2022.1021936
[4] Hanna P.E, Ouyang T, Tahir I et al. Sarcopenia, adiposity and large discordance between cystatin C and creatinine‐based estimated glomerular filtration rate in patients with cancer. J Cachexia Sarcopenia Muscle, 2024, 15 (3): 1187-1198. doi: 10.1002/jcsm.13469
[5] Lin Y.L, Wang C.H, Chang I.C, Hsu B.G. A novel application of serum creatinine and cystatin C to predict sarcopenia in advanced CKD. Front Nutr, 2022, 9: 828880. doi: 10.3389/fnut.2022.828880
[6] Silva-Tinoco R, Castillo-Martínez L, Cabrera-Victoria B et al. Prevalence of diabetes-related sarcopenia and its defining components within primary care: a cross-sectional study. Diabetes Epidemiology and Management, 2025, 18: 100252. doi: 10.1016/j.deman.2025.100252
[7] Lin T, Jiang T, Huang X et al. Diagnostic test accuracy of serum creatinine and cystatin C-based index for sarcopenia: a systematic review and meta-analysis. Age Ageing, 2024, 53 (1): afad252. doi: 10.1093/ageing/afad252
[8] Tang T, Xie L, Hu S et al. Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer. J Cachexia Sarcopenia Muscle, 2022, 13 (3): 1800-1810. doi: 10.1002/jcsm.12977